Obstacles to the development of a safe and effective attenuated pre-erythrocytic stage malaria vaccine

Ballou, 2004, Update on the clinical development of candidate malaria vaccines, Am. J. Trop. Med. Hyg., 71, 239, 10.4269/ajtmh.2004.71.239 Moore, 2004, Progress in DNA-based heterologous prime-boost immunization strategies for malaria, Immunol. Rev., 199, 126, 10.1111/j.0105-2896.2004.00138.x Nussenzweig, 1967, Protective immunity produced by the injection of X-irradiated sporozoites of Plasmodium berghei, Nature, 216, 160, 10.1038/216160a0 Nussenzweig, 1989, Rationale for the development of an engineered sporozoite malaria vaccine, Adv. Immunol., 45, 283, 10.1016/S0065-2776(08)60695-1 Nardin, 1990, Cellular and humoral immune responses to a recombinant P. falciparum CS protein in sporozoite-immunized rodents and human volunteers, Bull. WHO, 68, 85 Egan, 1993, Humoral immune responses in volunteers immunized with irradiated Plasmodium falciparum sporozoites, Am. J. Trop. Med. Hyg., 49, 166, 10.4269/ajtmh.1993.49.166 Krzych, 1995, T lymphocytes from volunteers immunized with irradiated Plasmodium falciparum sporozoites recognize liver and blood stage malaria antigens, J. Immunol., 155, 4072, 10.4049/jimmunol.155.8.4072 Scheller, 1995, Maintenance of protective immunity against malaria by persistent hepatic parasites derived from irradiated sporozoites, Proc. Nat. Acad. Sci. U.S.A., 92, 4066, 10.1073/pnas.92.9.4066 Hoffman, 2002, Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites, J. Infect. Dis., 185, 1155, 10.1086/339409 Berenzon, 2003, Protracted protection to Plasmodium berghei malaria is linked to functionally and phenotypically heterogeneous liver memory CD8+ T cells, J. Immunol., 171, 2024, 10.4049/jimmunol.171.4.2024 Luke, 2003, Rationale and plans for developing a non-replicating, metabolically active, radiation-attenuated Plasmodium falciparum sporozoite vaccine, J. Exp. Biol., 206, 3803, 10.1242/jeb.00644 Menard, 2005, Knockout malaria vaccine?, Nature, 433, 113, 10.1038/433113a Belnoue, 2004, Protective T cell immunity against malaria liver stage after vaccination with live sporozoites under chloroquine treatment, J. Immunol., 172, 2487, 10.4049/jimmunol.172.4.2487 Schellenberg, 1999, African children with malaria in an area of intense Plasmodium falciparum transmission: features on admission to the hospital and risk factors for death, Am. J. Trop. Med. Hyg., 61, 431, 10.4269/ajtmh.1999.61.431 Gupta, 1999, Immunity to non-cerebral severe malaria is acquired after one or two infections, Nat. Med., 5, 340, 10.1038/6560 Lyke, 2004, Incidence of severe Plasmodium falciparum malaria as a primary endpoint for vaccine efficacy trials in Bandiagara, Mali, Vaccine, 22, 3169, 10.1016/j.vaccine.2004.01.054 Lengeler, 2000, Insecticide-treated bednets and curtains for preventing malaria, Cochrane Database Syst. Rev., 2 Schellenberg, 2001, Intermittent treatment for malaria and anaemia control at time of routine vaccination in Tanzanian infants; a randomised, placebo-controlled trial, Lancet, 357, 1471, 10.1016/S0140-6736(00)04643-2 Massaga, 2003, IC. Effect of intermittent treatment with amodiaquine on anaemia and malaria fevers in Tanzania; a randomised, placebo-controlled trial, Lancet, 361, 1853, 10.1016/S0140-6736(03)13504-0 Alonso, 2004, J. Cohen. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial, Lancet, 364, 1411, 10.1016/S0140-6736(04)17223-1 Hurd, 2003, GA. In vitro methods for culturing vertebrate and mosquito stages of Plasmodium, Microbes Infect., 5, 321, 10.1016/S1286-4579(03)00034-0 Al-Olayan, 2002, Complete development of mosquito phases of the malaria parasite in vitro, Science, 295, 677, 10.1126/science.1067159 Farrugia, 2004, Plasma for fractionation: safety and quality issues, Haemophilia, 10, 334, 10.1111/j.1365-2516.2004.00911.x Heppner, 2004, 851 Sun, 2003, Protective immunity induced with malaria vaccine, RTS,S, is linked to Plasmodium falciparum circumsporozoite protein-specific CD4(+) and CD8(+) T cells producing IFN-gamma, J. Immunol., 171, 6961, 10.4049/jimmunol.171.12.6961 Kester, 2001, Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria, J. Infect. Dis., 183, 640, 10.1086/318534 Bejon, 2005, Calculation of liver-to-blood inocula, parasite growth rates, and preerythrocytic vaccine efficacy, from serial quantitative polymerase chain reaction studies of volunteers challenged with malaria sporozoites, J. Infect. Dis., 191, 619, 10.1086/427243 Alonso, 2005, Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial, Lancet, 366, 2012, 10.1016/S0140-6736(05)67669-6 Vuola, 2005, Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers, J. Immunol., 174, 449, 10.4049/jimmunol.174.1.449 Mueller, 2005, Genetically modified Plasmodium parasites as a protective experimental malaria vaccine, Nature, 433, 164, 10.1038/nature03188